Prospective adjuvant chemotherapy of mitomycin C plus HCFU for colorectal cancer (2d report) --6-year survival after surgery: Tokai Cooperative Study Group of Surgical Adjuvant Chemotherapy
Ichihashi, H.; Yamauchi, M.; Watanabe, T.; Takagi, H.; Kondo, T.
Gan no Rinsho. Japan Journal of Cancer Clinics 34(4): 451-456
1988
ISSN/ISBN: 0021-4949 PMID: 3128670 Document Number: 320788
A prospective randomized controlled trial of adjuvant chemotherapy for colorectal cancer was performed in forty-one institutions in Tokai district. In this study, effect of postoperative administration of mitomycin C (MMC) and followed by HCFU for more than 3 months (group B) was on the survival time compared with MMC alone (group A). Of 173 patients subjected to curative resection (group A = 80, group B = 93) for colorectal cancer, 148 patients including 69 cases of group A and 79 cases of group B were eligible for survival study. At six years after surgery, Kaplan-Meire's life table showed that the survival of group B was superior to that of group A (generalized Wilcoxon test: p = 0.0446). The difference of survival curves was more distinct (generalized Wilcoxon test: p = 0.0226) for patients of advanced stage those to have lymph node metastasis time and serosal inversion.